Opdivo for Head-Neck Cancers Too Costly for UK Patients, NICE Rules
News
Opdivo (nivolumab) likely will not be available for United Kingdom patients with head and neck cancers, because the U.K. cost-benefit agency, the National Institute for Health and Care Excellence (NICE), ... Read more